» Articles » PMID: 29483280

Swedish Nerve Growth Factor Mutation (NGF) Defines a Role for TrkA and P75 in Nociception

Overview
Journal J Neurosci
Specialty Neurology
Date 2018 Feb 28
PMID 29483280
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Nerve growth factor (NGF) exerts multiple functions on target neurons throughout development. The recent discovery of a point mutation leading to a change from arginine to tryptophan at residue 100 in the mature NGFβ sequence (NGF) in patients with hereditary sensory and autonomic neuropathy type V (HSAN V) made it possible to distinguish the signaling mechanisms that lead to two functionally different outcomes of NGF: trophic versus nociceptive. We performed extensive biochemical, cellular, and live-imaging experiments to examine the binding and signaling properties of NGF Our results show that, similar to the wild-type NGF (wtNGF), the naturally occurring NGF mutant was capable of binding to and activating the TrkA receptor and its downstream signaling pathways to support neuronal survival and differentiation. However, NGF failed to bind and stimulate the 75 kDa neurotrophic factor receptor (p75)-mediated signaling cascades (i.e., the RhoA-Cofilin pathway). Intraplantar injection of NGF into adult rats induced neither TrkA-mediated thermal nor mechanical acute hyperalgesia, but retained the ability to induce chronic hyperalgesia based on agonism for TrkA signaling. Together, our studies provide evidence that NGF retains trophic support capability through TrkA and one aspect of its nociceptive signaling, but fails to engage p75 signaling pathways. Our findings suggest that wtNGF acts via TrkA to regulate the delayed priming of nociceptive responses. The integration of both TrkA and p75 signaling thus appears to regulate neuroplastic effects of NGF in peripheral nociception. In the present study, we characterized the naturally occurring nerve growth factor NGF mutant that is associated with hereditary sensory and autonomic neuropathy type V. We have demonstrated for the first time that NGF retains trophic support capability through TrkA, but fails to engage p75 signaling pathways. Furthermore, after intraplantar injection into adult rats, NGF induced neither thermal nor mechanical acute hyperalgesia, but retained the ability to induce chronic hyperalgesia. We have also provided evidence that the integration of both TrkA- and p75-mediated signaling appears to regulate neuroplastic effects of NGF in peripheral nociception. Our study with NGF suggests that it is possible to uncouple trophic effect from nociceptive function, both induced by wild-type NGF.

Citing Articles

The Role of Biomarkers in Acute Pain: A Narrative Review.

Asimakopoulos T, Tsaroucha A, Kouri M, Pasqualucci A, Varrassi G, Leoni M Pain Ther. 2025; .

PMID: 40088258 DOI: 10.1007/s40122-025-00718-6.


NGF in Neuropathic Pain: Understanding Its Role and Therapeutic Opportunities.

Garcia-Dominguez M Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996814 PMC: 11854882. DOI: 10.3390/cimb47020093.


Neuropilin-1 inhibition suppresses nerve growth factor signaling and nociception in pain models.

Peach C, Tonello R, Damo E, Gomez K, Calderon-Rivera A, Bruni R J Clin Invest. 2024; 135(4).

PMID: 39589827 PMC: 11827847. DOI: 10.1172/JCI183873.


Neural and immune roles in osteoarthritis pain: Mechanisms and intervention strategies.

Zou Y, Liu C, Wang Z, Li G, Xiao J J Orthop Translat. 2024; 48:123-132.

PMID: 39220678 PMC: 11363721. DOI: 10.1016/j.jot.2024.07.010.


Neurotrophins and Their Receptors, Novel Therapeutic Targets for Pelvic Pain in Endometriosis, Are Coordinately Regulated by IL-1β via the JNK Signaling Pathway.

Yu J, Berga S, Zou E, Schrepf A, Clauw D, As-Sanie S Am J Pathol. 2023; 193(8):1046-1058.

PMID: 37164275 PMC: 10433690. DOI: 10.1016/j.ajpath.2023.04.007.


References
1.
Indo Y . Molecular basis of congenital insensitivity to pain with anhidrosis (CIPA): mutations and polymorphisms in TRKA (NTRK1) gene encoding the receptor tyrosine kinase for nerve growth factor. Hum Mutat. 2001; 18(6):462-71. DOI: 10.1002/humu.1224. View

2.
Lewin G, Mendell L . Nerve growth factor and nociception. Trends Neurosci. 1993; 16(9):353-9. DOI: 10.1016/0166-2236(93)90092-z. View

3.
Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B . Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998; 9(5):246-57. DOI: 10.1159/000017069. View

4.
Mufson E, Counts S, Perez S, Ginsberg S . Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother. 2008; 8(11):1703-18. PMC: 2631573. DOI: 10.1586/14737175.8.11.1703. View

5.
Murakawa Y, Zhang W, Pierson C, Brismar T, Ostenson C, Efendic S . Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab Res Rev. 2002; 18(6):473-83. DOI: 10.1002/dmrr.326. View